PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

Systematic Review of Device Parameters and Design of Studies Bridging Biologic-Device Combination Products Using Prefilled Syringes and Autoinjectors

(2020) Ping Hu et al.   AAPS Journal

Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug

(2020) Alexandre J. Debacker et al.   MOLECULAR THERAPY

Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides

(2019) Yanfeng Wang et al.   Expert Opinion on Drug Metabolism & Toxicology

Capacity limits of asialoglycoprotein receptor-mediated liver targeting

(2017) Charlotte Bon et al.   mAbs

Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events

(2016) Meir Preis et al.   BLOOD

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

(2015) Harry R. Büller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of Asialoglycoprotein Receptor 1 in Human Hepatocellular Carcinoma

(2013) Bin Shi et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations

(2010) Michael A. Gibney et al.   CURRENT MEDICAL RESEARCH AND OPINION

Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis

(2010) Ophira Salomon et al.   THROMBOSIS AND HAEMOSTASIS

Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers

(2010) Cecile Berteau   Patient Preference and Adherence

Reduced incidence of ischemic stroke in patients with severe factor XI deficiency

(2008) O. Salomon et al.   BLOOD